Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

RSS icon
Interview with Rebecca T. Hahn, MD, Professor of Medicine at Columbia University Irving Medical Center, Chief Scientific Officer of the Echo Core Lab at the Cardiovascular Research Foundation and Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center. She discusses some of the trends of growing use of interventional echocardiographic guidance in transcatheter structural heart procedures, the growing number of tricuspid valve procedures, and use of 3D ICE.

VIDEO: Trends in structural heart procedural imaging - a discussion with Rebecca Hahn

Rebecca T. Hahn, MD, Director of Interventional Echocardiography at the Columbia Structural Heart and Valve Center, discusses some of the trends in the growing use of interventional echocardiographic guidance in transcatheter structural heart procedures.

September 9, 2022
The Abbott MitraClip is the primary structural heart device used in transcatheter edge-to-edge repairs (TEER) of the mitral valve leaflets. The results of the COAPT trial dropped like a thunderclap Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, with several cardiologists predicting the MitraClip device will have a swift and lasting impact on the treatment of heart failure patients.

FDA warns of a new malfunction risk with Abbott’s MitraClip devices

When these malfunctions occur, the FDA explained, it leads to an increased risk of additional interventions.

September 8, 2022
surgery.jpg

SAVR after TAVR is rare, but linked to a high mortality risk

Researchers tracked data from more than 2,000 patients, noting that surgical bailout, infective endocarditis and paravalvular leak were the most common reasons for surgery to be required after TAVR. The full study was published in the American Journal of Cardiology.

September 7, 2022
heart patient

TEER safe and feasible for patients with atrial secondary mitral regurgitation

Atrial secondary mitral regurgitation has been linked to higher in-hospital mortality and hospitalization rates. 

September 6, 2022
Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation (CRF) and assistant professor of medicine at Columbia University College of Physicians and Surgeons, explains some of the highlights of the upcoming 2022 Transcatheter Cardiovascular Therapies (TCT) conference sponsored by CRF. #TCT #TCT2022

VIDEO: Previewing TCT 2022 in Boston with Juan Granada

Juan F. Granada, MD, president and chief executive officer of the Cardiovascular Research Foundation, previewed TCT 2022 for us, detailing what attendees can expect to see at the big show in Boston. 

September 6, 2022
The Abbott Cephea transcatheter mitral valve replacement (TMVR) system.

Cardiologist praises updated design of new TMVR system after historic interventional procedure

A care team with the Sanger Heart & Vascular Institute has shared details about its recent successes in TMVR and TAVR. Cardiologist Michael Rinaldi, MD, highlighted the importance of having "a coordinated team of specialists with expertise in treating valve diseases."

August 26, 2022
Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology. #TEER #TMVR

Risk of death increases when TEER patients present with hypertrophic cardiomyopathy

A team of Cleveland Clinic researchers tracked data from nearly 23,000 patients, sharing their findings in the American Journal of Cardiology. 

August 8, 2022
Mitral annular calcium (MAC) does not appear to have a negative effect on long-term transcatheter aortic valve replacement (TAVR) outcomes, according to new research published in the American Journal of Cardiology.

TAVR safe and effective for patients presenting with mitral annular calcium

Researchers from Cleveland Clinic reviewed data from more than 400 patients, presenting their findings in the American Journal of Cardiology.

July 28, 2022
Displaying 33 - 40 of 89
Design by Adaptive Theme